Riximyo (rituximab) is a biologic medicine that treats the pain and swelling of arthritis by suppressing part of the body's immune system.
Riximyo destroys a type of white blood cell that has a role in the body's immune system called the B-cell.
Riximyo can help in the treatment of a wide variety of diseases including rheumatoid arthritis and other autoimmune diseases, some types of cancer, and ultimately any disease that involves unwanted activity from B-cells. Riximyo is also used to help prevent tissue rejection in organ transplant patients.
Riximyo is available as an intravenous (IV) infusion.
Some patients feel better soon after receiving the medication, but in others, it can take longer: up to 3 or 4 months.
The manufacturer of Riximyo offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Watch Canadian rheumatologist Dr. Andy Thompson introduce Riximyo.
Watch Canadian rheumatologist Dr. Angèle Turcotte introduce Riximyo.
Drug Identification Number (DIN)